NIH Funded Patents Related to Trastuzumab (Herceptin), RePORT search, December 9, 2010
| Core Project Number |
Patent Number |
Filed |
Granted |
Assignee |
Patent Title |
| P30CA006516 |
4035566 |
Sep/25/1975 |
Jul/12/1977 |
Sidney Farber Cancer Institute, Inc. (Boston, MA) |
N-trifluoroacetyladriamycin-14-alkanoates and therapeutic compositions containing same |
| P30CA014051 |
4719177 |
Nov/12/1981 |
Jan/12/1988 |
Massachusetts Institute of Technology (Cambridge, MA) |
Production of complementary DNA representing RNA viral sequences by recombinant DNA methods and uses therefor |
| P30CA014051 |
4487829 |
Mar/23/1982 |
Dec/01/1984 |
Massachusetts Institute of Technology (Cambridge, MA) |
Production and use of monoclonal antibodies against adenoviruses |
| P30CA014051 |
4594318 |
Jun/17/1982 |
Jun/10/1986 |
Massachusetts Institute of Technology (Cambridge, MA) |
Isolation and localization of DNA segments |
| P30CA014051 |
4874845 |
Jun/13/1984 |
Oct/17/1989 |
Massachusetts Institute of Technology (Cambridge, MA) |
T lymphocyte receptor subunit |
| P30CA006516 |
4625014 |
Jul/10/1984 |
Nov/25/1986 |
Dana Farber Cancer Institute (Boston, MA) |
Cell-delivery agent |
| P30CA014051 |
4873190 |
Oct/31/1984 |
Oct/10/1989 |
Massachusetts Institute of Technology (Cambridge, MA) |
Heterodimeric T lymphocyte receptor |
| P30CA006516 |
4618492 |
May/13/1985 |
Oct/21/1986 |
Dana-Farber Cancer Institute, Inc. (Boston, MA) |
Acid-cleavable compound |
| P30CA006516 |
4542225 |
Aug/29/1985 |
Sep/17/1985 |
Dana-Farber Cancer Institute, Inc. (Boston, MA) |
Acid-cleavable compound |
| P30CA033572 |
4837165 |
Apr/20/1988 |
Jun/06/1989 |
Beckman Research Institute, City of Hope (Duarte, CA) |
Method for sequencing of peptides by carboxyl terminus degradation |
| P30CA014051 |
5017489 |
Aug/22/1988 |
May/21/1991 |
Massachusetts Institute of Technology (Cambridge, MA) |
Cytotoxic T lymphocte serine esterase and method for stimulation and inhibition |
| P30CA014051 |
4970296 |
Jul/27/1989 |
Nov/13/1990 |
Massachusetts Institute of Technology (Cambridge, MA), Board of Trustees of Leland Stanford Jr. University (Stanford, CA) |
Heterodimeric T lymphocyte receptor |
| R37CA011898 |
5212290 |
Dec/17/1990 |
May/18/1993 |
The Johns Hopkins University (Baltimore, MD), Duke University (Durham, NC) |
Antibodies specific for type II mutant EGTR |
| P30CA014051 |
5977321 |
Aug/08/1991 |
Nov/02/1999 |
Massachusetts Institute of Technology (Cambridge, MA) |
Heterodimeric T lymphocyte receptor subunit |
| R37CA011898 |
5407925 |
Nov/06/1991 |
Apr/18/1995 |
The Johns Hopkins University (Baltimore, MD), Duke University (Durham, NC) |
Regional chemotherapy within the central nervous system with 4-hydroperoxycyclophosphamide |
| R37CA011898 |
5401828 |
Dec/15/1992 |
Mar/28/1995 |
The Johns Hopkins University (Baltimore, MD), Duke University (Durham, NC) |
Structural alterations of the EGF receptor gene in human gliomas |
| R37CA011898 |
5316932 |
May/11/1993 |
May/31/1994 |
Duke University (Durham, NC) |
Homogeneous denatured human 06-guanine alkyltransferase prepared by immunoaffinity chromatography using monoclonal antibody specific for enzyme |
| P30CA006516 |
5502214 |
Jul/19/1993 |
Mar/26/1996 |
Dana Farber Cancer Institute (Boston, MA) |
1,2-benzoquinones and methods for making and using same |
| P30CA014051 |
5580961 |
Mar/18/1994 |
Dec/03/1996 |
Massachusetts Institute of Technology (Cambridge, MA) |
Heterodimeric T lymphocyte receptor subunit |
| P30CA014051 |
5882945 |
Jun/21/1994 |
Mar/16/1999 |
Massachusetts Institute of Technology (Cambridge, MA) |
Heterodimeric T lymphocyte receptor |
| P50CA058223 |
5728536 |
Jul/29/1994 |
Mar/17/1998 |
St. Jude Children's Hospital (Memphis, TN) |
Jak kinases and regulation of Cytokine signal transduction |
| P30CA014599 |
5618917 |
Feb/15/1995 |
Apr/08/1997 |
Arch Development Corporation (Chicago, IL) |
Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells |
| R37CA011898 |
5624659 |
Feb/22/1995 |
Apr/29/1997 |
Duke University (Durham, NC) |
Method of treating brain tumors expressing tenascin |
| R37CA011898 |
5814317 |
Mar/28/1995 |
Sep/29/1998 |
The Johns Hopkins University (Baltimore, MD), Duke University (Durham, NC) |
Structural alterations of the EGF receptor gene in human gliomas |
| P30CA014051 |
5804374 |
Apr/06/1995 |
Sep/08/1998 |
Massachusetts Insti. Technology (Cambridge, MA), Whitehead Insti. (Cambridge, MA), Pres. and Fellow of Harvard College (Cambridge, MA) |
Nuclear factors associates with transcriptional regulation |
| P30CA014599 |
5786344 |
Apr/17/1995 |
Jul/28/1998 |
Arch Development Corporation (Chicago, IL) |
Camptothecin drug combinations and methods with reduced side effects |
| P30CA014599 |
5698686 |
Apr/28/1995 |
Dec/16/1997 |
Arch Development Corporation (Chicago, IL) |
Yeast telomerase compositions |
| R01CA055306 |
5663144 |
May/03/1995 |
Sept 2, 1997 |
The Trustees of the University of Pennsylvania (Philadelphia, PA) |
Compounds that bind to p185 and methods of using the same |
| R37CA038173 |
5866323 |
May/22/1995 |
Feb/02/1999 |
Case Western Reserve University (Cleveland, OH), Medical College of Ohio (Toledo, OH) |
Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor .beta. and homologous growth controlling factors |
| R37CA011898 |
5710010 |
Jun/02/1995 |
Jan/28/1998 |
The Johns Hopkins University (Baltimore, MD), Duke University (Durham, NC) |
Assays for the presence of a mutant EGF receptor |
| R37CA011898 |
5981725 |
Jun/07/1995 |
Nov/09/1999 |
The Johns Hopkins University (Baltimore, MD), Duke University (Durham, NC) |
Structural alterations of the EGF receptor gene in human tumors |
| P30CA068485 |
5891857 |
Feb/20/1996 |
Apr/06/1999 |
Vanderbilt University (Nashville, TN), University of Washington (Seattle, WA) |
Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins |
| P50CA058223 |
6136595 |
Jun/18/1996 |
Oct/24/2000 |
St. Jude Children's Hospital (Memphis, TN) |
Jak kinases and regulations of cytokine signal transduction |
| P30CA014599 |
6043216 |
Apr/10/1997 |
Mar/28/2000 |
Arch Development Corporation (Chicago, IL) |
Methods and composition for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells |
| P30CA014599 |
5916752 |
Sep/26/1997 |
Jun/29/1999 |
Arch Development Corporation (Chicago, IL) |
Telomerase screening methods |
| P50CA058223 |
6210654 |
Oct/08/1997 |
Apr/03/2001 |
St. Jude Children's Hospital (Memphis, TN) |
Jak kinases and regulation of cytokine signal transduction |
| P30CA068485 |
6177410 |
Dec/05/1997 |
Jan/23/2001 |
Vanderbilt University (Nashville, TN), University of Washington (Seattle, WA) |
Therapeutic methods for prostate cancer |
| R01CA039930 |
7183401 |
Mar/20/1998 |
Feb/27/2007 |
Board of Regents, the University of Texas System (Austin, TX) |
NOEY2 gene compositions and methods of use |
| P30CA068485 |
6149903 |
Jun/18/1998 |
Nov/21/2000 |
Vanderbilt University (Nashville, TN), University of Washington (Seattle, WA) |
Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins |
| P30CA014051 |
5189147 |
Nov/14/1998 |
Feb/23/1993 |
Massachusetts Institute of Technology (Cambridge, MA) |
Meterodimeric T lymphocyte receptor antibody |
| R37CA011898 |
6127126 |
Mar/09/1999 |
Oct/03/2000 |
The Johns Hopkins University (Baltimore, MD), Duke University (Durham, NC) |
Method for diagnosing glioma associated with structural alterations of the EGF receptor gene in human tumors |
| P30CA014599 |
6387619 |
Jun/30/1999 |
May/14/2002 |
Arch Development Corporation (Chicago, IL) |
Telomerase compositions and methods |
| P50CA058223 |
6969760 |
Sep/17/1999 |
Nov/29/2005 |
St. Jude Children's Hospital (Memphis, TN) |
Jak kinases and regulation of cytokine signal transduction |
| P50CA083636 |
6734172 |
Nov/16/1999 |
May/11/2004 |
Pacific Northwest Research Institute (Seattle, WA) |
Surface receptor antigen vaccines |
| P30CA068485 |
6555321 |
Feb/14/2000 |
Apr/29/2003 |
Vanderbilt University (Nashville, TN) |
Methods for determining cell responses through EphB receptors |
| P30CA014599 |
6482934 |
Mar/28/2000 |
Nov/19/2002 |
Arch Development Corporation (Chicago, IL) |
Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells |
| R01AG014343 |
6399743 |
May/12/2000 |
Jun/04/2002 |
Dept. of Veterans Affairs (Washington, DC) |
Isolation and characterization of a rat epidermal growth factor related protein |
| P30CA068485 |
6743823 |
Jun/01/2000 |
Jun/01/2004 |
Vanderbilt University (Nashville, TN) |
Therapeutic methods relating to human carbamyl phosphate synthetase I polymorphism |
| R37CA011898 |
6455498 |
Sep/19/2000 |
Sep/24/2002 |
The Johns Hopkins University (Baltimore, MD) |
Structural alterations of the EGF receptor genes in human tumors |
| P30CA014051 |
7008780 |
May/10/2001 |
Mar/07/2006 |
Massachusetts Institute of Technology (Cambridge, MA) |
Chimeric DNA-binding proteins |
| P30CA033572 |
6951651 |
Aug/20/2003 |
Oct/04/2005 |
City of Hope (Durant California) |
CTL epitope analogs |
| P30CA033572 |
7122348 |
Dec/11/2003 |
Oct/17/2006 |
City of Hope (Durant California) |
AAV2 Rep protein fusions |
| M01RR000037 |
7138389 |
Nov/15/2004 |
Nov/21/2006 |
University of Washington (Seattle, WA) |
Oral androgen therapy using modulators of testosterone bioavailability |